TX-KINAXIS
Kinaxis® Inc. (TSX: KXS), the leading supply chain management platform, today announced collaborations with two prominent non-profit organizations – Women Who Code and Ellen MacArthur Foundation – to accelerate the company’s vision to preserve the planet’s resources and enrich the human experience. The partnerships were announced within the company’s new 2023 Sustainability Report which highlights the latest environmental, social, and governance (ESG) metrics to coincide with annual financial reporting and disclosures.
Kinaxis will work with Women Who Code, whose mission is to empower diverse women to excel in technology careers and the Ellen MacArthur Foundation, which advocates for the creation of a circular economy to eliminate waste and pollution, circulate products and materials, and regenerate nature.
Both organizations are focused on supporting and elevating innovators and changemakers to solve some of the world’s most pressing problems, which mirrors how Kinaxis is approaching solving the complexities of supply chain.
“Both Women Who Code and the Ellen MacArthur Foundation are committed to creating a world where the only limiting factor is your own imagination. We couldn’t be more thrilled to explore ways we can work with them as supply chain resiliency and sustainability take on new levels of importance in our new era of never-ending disruptions,” said John Sicard, president and chief executive officer at Kinaxis. “Our ambition to power the world’s supply chains is a big one and we know we can’t do it all on our own which is why collaborations with likeminded organizations are so critical to helping us advance a circular economy and socially responsible future for all.”
Women Who Code provides engineers, developers, data scientists, architects, designers and other technologists with the tools, resources, and opportunities they need to grow and succeed in their tech related careers. In keeping with the company’s commitment to shaping a more inclusive and equitable future for women in tech, Kinaxis will engage with the organization by ramping up membership recruitment efforts, establishing a new mentorship program and providing resources that spark interest in supply chain careers.
By becoming a Member of the Ellen MacArthur Foundation’s Network, Kinaxis will collaborate with the organization’s extensive network of circular economy leaders and practitioners to advance circular practices in the industry and get involved with groundbreaking research projects designed to drive innovation at scale. Moving away from a ‘take, make, waste’ linear model, the circular economy offers businesses the opportunity to redesign their supply chains to meet these needs, as well as reduce costs and cut greenhouse gas emissions.
Sicard continues: “As the single largest consumer of the Earth’s natural resources – whether it’s the materials used to make something, the resources required to store something, or the emissions expelled to ship something – supply chains are poised to make a significant positive impact, not just because regulations demand it.”
With more than 40,000 users in 100+ countries, Kinaxis works with some of the world’s biggest brands in sectors such as CPG, automotive, high tech, life sciences and more. Its AI-powered technology and patented concurrency technique allows companies to orchestrate their supply chain network end-to-end from strategic planning to last-mile delivery. Kinaxis technology helps companies that supply the agricultural industry with 40% of the world’s tractors, helps keep more than 110,000,000,000 teeth clean each year, and ensures more than 35 million pets are fed nutritious meals each year.
More details on the new partnerships and the company’s corporate giving program can be found in the 2023 Sustainability Report.
To learn more about Kinaxis and its supply chain management solutions, please visit Kinaxis.com.
About Kinaxis
Kinaxis is a global leader in modern supply chain management. We serve supply chains and the people who manage them in service of humanity. Our software is trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. We combine our patented concurrency technique with a human-centered approach to AI to empower businesses of all sizes to orchestrate their end-to-end supply chain network, from multi-year strategic planning through down-to-the-second execution and last-mile delivery. For more news and information, please visit kinaxis.com or follow us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305961661/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom